期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

盐酸帕洛诺司琼预防化疗所致恶心呕吐的疗效及安全性30例分析 被引量：4

Efficacy and Safety of Palonosetron Hydrochloride for Preventing 30 Cases with Chemotherapyinduced Nausea and Vomiting
原文传递
导出
摘要 [目的]观察盐酸帕洛诺司琼防治化疗所致恶心呕吐的疗效及安全性。[方法]60例非小细胞肺癌患者随机分为用盐酸帕洛诺司琼组和阿扎司琼组,每组30例。观察两组在控制急性呕吐(24h内)和延迟性呕吐(24～96h)的疗效差别及毒副反应情况。[结果]盐酸帕洛诺司琼和阿扎司琼防治急性呕吐的有效率(CR+PR)分别为93%和87%(P=0.667),防治延迟性呕吐的有效率分别为70%和30%(P=0.002)。两组分别有20%和23%的患者出现便秘、腹胀及头痛,两组间毒副反应比较无显著性差异(P>0.05)。[结论]盐酸帕洛诺司琼防治化疗所致的恶心呕吐疗效优于阿扎司琼,且安全性好,值得临床推广。
作者 罗红兰 刘静 董晓荣 刘莉
机构地区 湖北省黄冈市中心医院 华中科技大学同济医学院附属协和医院
出处 《肿瘤学杂志》 CAS 2009年第11期1052-1053,共2页 Journal of Chinese Oncology
关键词 盐酸帕洛诺司琼 阿扎司琼 药物疗法 恶心 呕吐
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献7

  • 1Hesketh PJ.Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J].Cancer Invest,2000,18:163-173.
  • 2Geling O,Eichler HG.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications[J].J Clin Oncol,2005,23(6):1289-1294.
  • 3Gralla R,Lichinitser M,Vegt SV,et al.Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy:results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron[J].Ann of Oncol,2003,14(10):1570-1577.
  • 4Eisenberg P,Figueroa-Vadillo J,Zamora R,et al.Improved prevention of moderately emeto-genic chemotherapy-induced nausea and vomiting with palonosetron,a pharmacologically novel 5-HT3 receptor antagonist:results of a phase Ⅲ,single-dose trial versus dolasetron[J].Cancer,2003,98(11):2473-2482.
  • 5Piraccini G,Stolz R,Tei M,et al.Pharmacokinetic features of a novel 5-HT3-receptor antagonist:palonosetron (RS 25259-197)[J].Proc Am Soc Clin Oncol,2001; 20:400a (Abstr 1595).
  • 6Oge A,Alkis N,Oge O,et al.Comparison of granisetron,ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin[J].J Chemother,2000,12:105-108.
  • 7Hickok JT,Roscoe JA,Morrow GR,et al.5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin:a URCC CCOP randomised controlled trial[J].Lancet Oncol,2005,6(10):765-772.

共引文献47

同被引文献30

  • 1陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量：48
  • 2Gmlh R, Lichinitser M, Van Der Veqt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a doubleblind randomized phase trial comparing single doses of palonosetron with ondansetron[J]. Ann Oncol, 2003, 4(10):1570-1577.
  • 3Johnston D, Latreille J, Laberge F, et al. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP).A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)(Meeting abstract)[J]. Proc Am Soc Clin Oncol, 1995,34:529-529.
  • 4周际昌.实用肿瘤手册[M].北京:人民卫生出版社,1999:480-481.
  • 5Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-TH3 receptor[J]. Anesth Analg, 2008, 107(2):469-478.
  • 6Moura Barbosa AJ, De Rienzo F, Rimos MJ, et al. Computational analysis of ligand recognition sites of homo-and heteropentameric 5-HT3 receptors[J]. Eur J Med Chem, 2010, 45(11):4746-4760.
  • 7Wong EH, Clark R, Leung E, et al. The interaction of RS25259-197, a potent and selective antagonist, with 5- HT3 receptors in vitro[J]. Brnr J Pharmacol, 1995, 114(4): 851-859.
  • 8Miller RC, Galvan M, Gittos MW, et al. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors[J]. Drug Dev Res, 1993, 28(1):87-93.
  • 9Tomek R, Vrdoljak E, Vrbanec D, et al. Croatian guidelines for prevention of chemotherapy induced nausea and vomiting [J]. Lijec Vjesn, 2009, 131(3-4): 49.
  • 10Botrel T E, Clark O A, Clark L, et al. Efficacy of palonosetron (PAL) eompared to other semtonin inhibitors (5 - HT3R) in preventing chemotherapy - induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenie ( MoHE ) treatment: systematic review and meta- analysis[J]. Support Care Cancer, 2011, 19(6) .' 823.

引证文献4

二级引证文献12

肿瘤学杂志
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部